Animal model for chronic obstructive pulmonary disease and cystic fibrosis
View Patent ↗A nonhuman transgenic mammal is described whose genome comprises a promoter construct operably linked to a heterologous DNA encoding an epithelial sodium channel β subunit, wherein said promoter construct directs expression of the epithelial sodium channel β subunit in lung epithelial cells of said animal, and wherein said transgenic mammal has increased lung mucus retention as compared to the corresponding wild-type mammal. The animal is useful in screening compounds for activity in treating lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.
1. A transgenic mouse comprising in its genome, a transgene construct comprising a nucleic acid sequence that encodes mouse epithelial sodium channel (EnaC) β operably linked to a mammalian lung epithelial cell promoter, wherein said EnaC β is expressed in lung epithelial cells, and wherein said transgenic mouse exhibits increased lung mucus retention, increased lung mucus plugging and airway inflammation, and increased mortality, as compared to a corresponding wild-type mouse.
2. The transgenic mouse of claim 1 , wherein said mammalian lung epithelial cell promoter is selected from the group consisting of the CCSP promoter, the surfactant protein C promoter, the cytokeratin 18 promoter, and the human forkhead homologue 4 promoter.
3. The transgenic mouse of claim 1 , wherein said transgenic mouse has increased mortality at 30 days of age as compared to the corresponding wild-type mouse.
4. The transgenic mouse of claim 1 , wherein said transgenic mouse exhibits a cystic fibrosis or chronic obstructive pulmonary disease phenotype not exhibited by the corresponding wild-type mouse.
5. A transgenic mouse comprising in its genome, a transgene construct comprising a nucleic acid sequence that encodes mouse epithelial sodium channel (EnaC) β operably linked to a rat Clara cell secretory protein (CCSP) promoter, wherein EnaC β is expressed in lung epithelial cells, and wherein said transgenic mouse exhibits increased lung mucus retention, increased lung mucus plugging and airway inflammation, and increased mortality, as compared to a corresponding wild-type mouse.